Maze Therapeutics, Inc. (MAZE) Stock

Maze Therapeutics, Inc. (MAZE) is a Healthcare stock trading at $25.66 (as of 2026-06-18), with a market capitalization of $1.46B and a trailing P/E of -11.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Maze Therapeutics, Inc. is a clinical stage biopharmaceutical company developing oral small-molecule medicines for renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its programs include MZE829 for APOL1 kidney disease (phase II) and MZE782 for chronic kidney disease (phase I).

Valuation — source: SEC EDGAR (first-party)
Price	$25.66
Market Cap	$1.46B
P/E Ratio	-11.3
EV / EBITDA	-9.9
Price / Book	4.29
Price / Sales	8.74
DCF Value (model)	$-35.04
DCF Upside vs Price	-236.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$167.50M
Net Margin	31.2%
Return on Equity	-35.9%
Debt / Equity	0.11
Current Ratio	17.88
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	-178.6%
FCF Growth (YoY)	-121.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	16.51 (safe)

Valuation vs Sector & Industry
Stock P/E	-11.3
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-153.7%
vs Industry	-165.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Frazier Life Sciences Management, L.P. ($136.33M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jason V. Coloma
Employees	125
Country	US
IPO Date	2025-01-31

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.